Back to Search
Start Over
Bromotyrosines in sputum proteins and treatment effects of terbutaline and budesonide in asthma.
- Source :
-
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2009 Oct; Vol. 103 (4), pp. 348-53. - Publication Year :
- 2009
-
Abstract
- Background: Inhaled corticosteroids are widely used in the treatment of persistent asthma, usually combined with inhaled beta2-agonists. Previous research suggests that short-acting beta2-agonists (SABAs) may downregulate the anti-inflammatory effects of inhaled corticosteroids, thereby increasing asthma morbidity.<br />Objective: To determine whether 3-bromotyrosine and 3,5-dibromotyrosine levels, specific markers of eosinophil activation, reflect treatment effects on airway inflammation of inhaled corticosteroids and SABAs and support previous conclusions.<br />Methods: Levels of 3-bromotyrosine and 3,5-dibromotyrosine were measured in sputum supernatants using stable isotope dilution gas chromatography-mass spectrometry in a randomized, placebo-controlled, crossover study of treatment with terbutaline, budesonide, and their combination in patients with persistent asthma. Thirty-four individuals were randomized, and 28 completed the study.<br />Results: Treatment with budesonide lowered median 3-bromotyrosine levels compared with treatment with placebo, terbutaline, and budesonide-terbutaline (0.24 vs 0.64, 0.62, and 0.43 3-bromotyosine/tyrosine [mmol/mol]; P < .05) and lowered median 3,5-dibromotyrosine levels compared with placebo and terbutaline treatments (0.04 vs 0.11 and 0.07 3,5-dibromotyrosine/ tyrosine [mmol/mol], P < .05). Unlike eosinophil numbers, 3-bromotyrosine and 3,5-dibromotyrosine levels did not increase with terbutaline treatment compared with placebo treatment but were significantly raised when terbutaline was added to budesonide treatment. 3-Bromotyrosine levels correlated significantly with eosinophil cationic protein levels in all groups.<br />Conclusions: 3-Bromotyrosine and 3,5-dibromotyrosine levels reflect treatment effects in asthma and support previous findings that SABAs impair the anti-inflammatory effects of inhaled corticosteroids. In addition to eosinophil numbers and eosinophil cationic protein levels, these modified tyrosine residues provide useful information about the inflammatory state of the airways.
- Subjects :
- Adolescent
Adult
Asthma immunology
Cross-Over Studies
Double-Blind Method
Eosinophils drug effects
Eosinophils immunology
Female
Humans
Male
Middle Aged
Respiratory Function Tests
Sputum cytology
Tyrosine metabolism
Young Adult
Adrenergic beta-Agonists administration & dosage
Asthma drug therapy
Asthma metabolism
Bronchodilator Agents administration & dosage
Budesonide administration & dosage
Sputum metabolism
Terbutaline administration & dosage
Tyrosine analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1081-1206
- Volume :
- 103
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 19852201
- Full Text :
- https://doi.org/10.1016/S1081-1206(10)60536-4